Battle Card: TRIO Pharmaceuticals Sales Trigger
Mikael Dolsten joins TRIO. Activate your CRO pitch now. Quick R&D intel to fuel your pipeline and secure commission-ready deals.
Published on
Do not index
Do not index
🚀 Battle Card: TRIO Pharmaceuticals
Quick trigger:
Pro Tip: This TRIO Pharmaceuticals sales trigger is your green light to engage their R&D and decision team now.
👤 Decision Maker in the News
- Mikael Dolsten, M.D., Ph.D., Chairman of the Board of Directors · 🔗 [LinkedIn](https://www.linkedin.com/company/trio-pharmaceutials-inc/?viewAsMember=true)
💡 Why It Matters
- Bringing in a veteran CSO and R&D leader slashes time-to-clinic risk and boosts investor confidence. → Source
🎯 Core Pain Point
- Accelerating preclinical to IND-enabling studies
- Differentiating TRAILBody™ platform in a crowded oncology antibody market
💰 What to Pitch
- Primary: High-throughput antibody screening services → accelerate candidate nomination and optimization
- Expansion: Regulatory strategy consulting → streamline IND submissions and reduce review cycles
🗺️ Quick Context
- HQ: San Carlos, CA
- Employees: ≈ 30
- Rev: ≈ $0 M (pre-revenue)
🤼 Competitive Intel
Which other vendors you’ll probably face to win TRIO Pharmaceuticals’s business.
- Charles River Laboratories — Preclinical CRO
- Unique edge: Integrated in vivo oncology models
- Evaluated by R&D for translational relevance
- WuXi AppTec — Preclinical CRO
- Unique edge: Global assay & biomanufacturing platforms
- Evaluated by CSO for scalability
- Catalent — CMC & Manufacturing
- Unique edge: End-to-end GMP support
- Evaluated by Dir. of Ops for manufacturing readiness
✅ Do-Now Checklist
Connect with the decision maker on LinkedIn (link above)
Generate email referencing this TRIO Pharmaceuticals sales trigger with the Copy-My-Prompt block (Step 7) and send first touch
Schedule follow-ups in CRM (Day 3 & Day 10)
Next Step
Get TRIO Pharmaceuticals sales trigger intel like this daily—no fluff, all pipeline.
Subscribe to NewsletterForLeads
🧠 Copy My Prompt for Personalized Cold Outreach
────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY = ❑≈ TBD❑
OFFER_BRIEF = ❑High-throughput antibody screening services❑
PROOF_METRIC = ❑40% faster candidate nomination❑
CTA_STYLE = ❑quick_call❑
TONE = ❑friendly❑
────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME = Mikael
COMPANY = TRIO Pharmaceuticals
DEPT = R&D
SIZE = ≈30
BOTTLENECK = Accelerating preclinical to IND-enabling studies
EVENT = Mikael Dolsten joins as Chairman
DETAIL = TRAILBody™ antibodies kill tumor cells without toxic payload
PAIN = current antibody therapies face relapses and resistance reducing response
SRC = http://cts.businesswire.com/ct/CT?id=ftfLlWd9aZbF2NXfwppam3Bd664=&newsLang=en&newsId=20251008112766&div=41152219
SIM_CO = Genentech
WIN_METRIC = 40% faster candidate nomination
NEXT_SIZE = 50
EMP_EST = ≈30
REV_EST = ≈0 M
────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.
Validate any ≈ guesses via SRC.
EMAIL (keep breaks):
Subject: ≈30-person R&D
Mikael—noticed your R&D team is ≈30.
That’s when Accelerating preclinical to IND-enabling studies slows growth.
We helped Genentech fix this with High-throughput antibody screening services.
Result: 40% faster candidate nomination.
Quick call?
PS—next bottleneck hits ≈50.
DM ≤45 words, TONE:
Saw your post about TRAILBody™ antibodies kill tumor cells without toxic payload — current antibody therapies face relapses and resistance reducing response.
High-throughput antibody screening services. 40% faster candidate nomination.
Quick chat?```